Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Newsoara Ok’d to Start China Phase III Trial of Bowel Function Drug

publication date: May 6, 2022

Shanghai Newsoara Biopharma has been cleared to proceed with its China Phase III trial of LB1148, which is designed to accelerate the return of bowel function in adult patients following bowel/abdominal surgery. The candidate is an oral broad-spectrum serine protease inhibitor that is aimed at neutralizing digestive proteases released from the gut during surgery. Newsoara in-licensed greater China rights to the drug from Palisade Bio of Carlsbad, CA, which recently announced US approval of a similar Phase III trial. Newsoara is a Shanghai in-licensing company with an R&D facility in Suzhou BioBay. More details....

Stock Symbol: (NSDQ: PALI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here